Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
PathwayKEGG_MEDICUS_REFERENCE_TIGHT_JUNCTION_ACTIN_SIGNALING_PATHWAY

CLDN34 ARPC4

9.99e-053762M47769
InteractionUNK interactions

PTGES3 USP34 ARPC4

7.99e-0540853int:UNK
InteractionSULT1A1 interactions

PTGES3 USP34

1.08e-046752int:SULT1A1
InteractionSNRNP200 interactions

PTGES3 USP34 CMTR1

1.14e-0446053int:SNRNP200
InteractionTTLL12 interactions

USP34 ARPC4

3.30e-0411752int:TTLL12
InteractionNT5C2 interactions

PTGES3 CMTR1

3.30e-0411752int:NT5C2
InteractionAGO4 interactions

PTGES3 USP34

3.36e-0411852int:AGO4
CoexpressionGSE16450_CTRL_VS_IFNA_6H_STIM_MATURE_NEURON_CELL_LINE_DN

PTGES3 ARPC4 CMTR1

1.50e-0520073M7423
ToppCellSmart-seq2-bone_marrow_(Smart-seq2)-lymphocytic-B_lymphocytic-plasmablast|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

EFCAB10 ZNF606

1.67e-04128723c810fc4934dee4de2b8b64a2e152547b08c6f8d
ToppCell(04)_Pre-ciliated-(3)_72hpi|(04)_Pre-ciliated / shred by cell type and Timepoint

EFCAB10 PTGES3

3.60e-0418872f911dc61b008b60aaa2a1e9354085f480a669e2c
ToppCellfacs-MAT-Fat-18m|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PTGES3 ARPC4

3.60e-04188727f0cda7aab442aa9511d4c35569ec2389e014a71
ToppCellcritical-Epithelial-Ciliated-diff|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

EFCAB10 PTGES3

3.83e-0419472176090949b53c043c58df63ad8cf4f486b350bdc
ComputationalGenes in the cancer module 177.

PTGES3 ARPC4

5.18e-0410142MODULE_177
DrugCloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; HL60; HG-U133A

USP34 ARPC4 ZNF606

2.21e-05198731443_DN
Drugpioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A

USP34 ZNF606

1.31e-03183727088_DN
DrugCefadroxil [50370-12-2]; Down 200; 11uM; HL60; HT_HG-U133A

USP34 ARPC4

1.36e-03186721323_DN
Drugnickel subsulfide

PTGES3 ARPC4

1.39e-0318872ctd:C017557
DrugPhenacetin [62-44-2]; Up 200; 22.4uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.40e-03189722832_UP
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.42e-03190726998_UP
Drugcarbamazepine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

USP34 ZNF606

1.42e-0319072952_UP
DrugProchlorperazine dimaleate [84-02-6]; Up 200; 6.6uM; HL60; HT_HG-U133A

USP34 ARPC4

1.42e-03190721286_UP
DrugAmbroxol hydrochloride [23828-92-4]; Down 200; 9.6uM; HL60; HG-U133A

USP34 ARPC4

1.44e-03192721623_DN
Drug5230742; Down 200; 17uM; MCF7; HT_HG-U133A_EA

USP34 ARPC4

1.44e-0319272970_DN
DrugAvermectin B1 [71751-41-2]; Up 200; 4.8uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.44e-03192727218_UP
DrugSR-95639A [115767-94-7]; Up 200; 10uM; HL60; HT_HG-U133A

USP34 ZNF606

1.46e-03193721336_UP
DrugMelatonin [73-31-4]; Down 200; 17.2uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.46e-03193723293_DN
DrugIopanoic acid [96-83-3]; Down 200; 7uM; HL60; HT_HG-U133A

USP34 ARPC4

1.47e-03194722965_DN
DrugGalanthamine hydrobromide [1953-04-4]; Down 200; 10.8uM; MCF7; HT_HG-U133A

USP34 ARPC4

1.47e-03194722787_DN
DrugAcemetacin [53164-05-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A

USP34 ARPC4

1.47e-03194727442_UP
DrugPiroxicam [36322-90-4]; Down 200; 12uM; HL60; HG-U133A

ARPC4 ZNF606

1.47e-03194721405_DN
DrugAmoxapine [14028-44-5]; Down 200; 12.8uM; MCF7; HT_HG-U133A

USP34 ARPC4

1.49e-03195724996_DN
DrugCAY10397; Down 200; 10uM; PC3; HT_HG-U133A

USP34 ARPC4

1.50e-03196727087_DN
DrugAG-028671 [847803-03-6]; Down 200; 10uM; PC3; HT_HG-U133A

ARPC4 ZNF606

1.50e-03196726582_DN
DrugMafenide hydrochloride [138-37-4]; Down 200; 18uM; PC3; HT_HG-U133A

USP34 ZNF606

1.52e-03197722124_DN
DrugThalidomide [50-35-1]; Down 200; 15.4uM; PC3; HT_HG-U133A

USP34 ARPC4

1.52e-03197722095_DN
DrugPheniramine maleate [132-20-7]; Down 200; 11.2uM; HL60; HG-U133A

USP34 ARPC4

1.52e-03197721992_DN
Drugnifedipine; Down 200; 10uM; MCF7; HG-U133A

USP34 ARPC4

1.52e-0319772335_DN
DrugSulfabenzamide [127-71-9]; Down 200; 14.4uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.52e-03197722814_DN
DrugBuspirone hydrochloride [33386-08-2]; Up 200; 9.4uM; HL60; HT_HG-U133A

USP34 ARPC4

1.52e-03197721282_UP
DrugRibavirin [36791-04-5]; Down 200; 16.4uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.52e-03197726018_DN
DrugSpironolactone [52-01-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.52e-03197726255_UP
Druggenistein; Down 200; 10uM; MCF7; HT_HG-U133A_EA

USP34 ARPC4

1.52e-03197721015_DN
DrugSB 202190; Down 200; 1uM; MCF7; HT_HG-U133A

USP34 ARPC4

1.52e-03197726909_DN
DrugLY294002; Down 200; 0.1uM; MCF7; HG-U133A

USP34 ARPC4

1.52e-0319772424_DN
Drug5194442; Down 200; 20uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.52e-03197726558_DN
DrugEnalapril maleate [76095-16-4]; Up 200; 8.2uM; MCF7; HT_HG-U133A

USP34 ARPC4

1.54e-03198727428_UP
DrugClorsulon [60200-06-8]; Up 200; 10.6uM; HL60; HG-U133A

USP34 ZNF606

1.54e-03198721735_UP
DrugSulfasalazine [599-79-1]; Up 200; 10uM; HL60; HG-U133A

USP34 ZNF606

1.54e-03198721733_UP
DrugLidocaone hydrochloride [73-78-9]; Down 200; 14.8uM; HL60; HG-U133A

USP34 ARPC4

1.54e-03198721999_DN
DrugIobenguane sulfate; Down 200; 10.8uM; PC3; HT_HG-U133A

USP34 ARPC4

1.54e-03198727299_DN
DrugTroleandomycin [2751-09-9]; Up 200; 5uM; HL60; HG-U133A

USP34 ARPC4

1.54e-03198721965_UP
DrugPiracetam [7491-74-9]; Up 200; 28.2uM; HL60; HG-U133A

USP34 ARPC4

1.54e-03198721710_UP
DrugScopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; HL60; HG-U133A

USP34 ARPC4

1.54e-03198721415_DN
DrugMilrinone [78415-72-2]; Down 200; 19uM; PC3; HT_HG-U133A

USP34 ARPC4

1.55e-03199725856_DN
Drugfelodipine; Down 200; 10uM; MCF7; HG-U133A

USP34 ARPC4

1.55e-0319972337_DN
DrugCefotetan [69712-56-7]; Down 200; 7uM; HL60; HT_HG-U133A

USP34 CMTR1

1.55e-03199721319_DN
DrugFlurbiprofen [5104-49-4]; Down 200; 16.4uM; MCF7; HT_HG-U133A

USP34 ZNF606

1.55e-03199725634_DN
DrugPHA-00816795 [212631-79-3]; Down 200; 10uM; PC3; HT_HG-U133A

USP34 ZNF606

1.55e-03199727072_DN
DrugTrimetazidine dihydrochloride [13171-25-0]; Up 200; 11.8uM; HL60; HG-U133A

ARPC4 CMTR1

1.55e-03199721727_UP
DrugTerazosin hydrochloride [63590-64-7]; Down 200; 9.4uM; PC3; HT_HG-U133A

USP34 CMTR1

1.57e-03200725831_DN
DiseaseQRS duration

PTGES3 USP34

1.48e-0329862EFO_0005055
Diseaseatrial fibrillation

PTGES3 USP34

2.29e-0337162EFO_0000275

Protein segments in the cluster

PeptideGeneStartEntry
FFMDNSNIVAMFEMM

EFCAB10

61

A6NFE3
FFLNRAAMKMANMDF

CMTR1

231

Q8N1G2
AAMKMANMDFVFDRM

CMTR1

236

Q8N1G2
MRFMMMRAENFFILR

ARPC4

91

P59998
FNMFALRNMSMRMFE

CLDN34

106

H7C241
DMSNFDRFSEMMNNM

PTGES3

116

Q15185
FNTMRYTFNMVTMMK

USP34

2086

Q70CQ2
YHMNQSTAMRQMVFM

ZNF606

186

Q8WXB4